News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pfizer Inc. (PFE) Sees Something Special In MissionTherapeutics Ltd, Backs Co With $32 Million Series B


11/18/2013 8:27:42 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

A Cambridge company developing new drugs focused around DNA damage and genetically defined cancers has attracted investment from another pharma giant, Pfizer, in its latest funding round, a £20 million Series B. Pfizer Venture Investments was the only new investor in Mission Therapeutics’ Series B round, which was led by existing investor Sofinnova Partners and also included Imperial Innovations, SR One and Roche Venture Fund, which means it now has three major pharmaceutical companies backing it – SR One is GlaxoSmithKline’s corporate healthcare VC fund. Based at Babraham Research Campus, Mission is a Cambridge University spin-out established by the same team that set up Kudos Pharmaceuticals, which was eventually acquired by AstraZeneca for $210m in 2006.

Help employers find you! Check out all the jobs and post your resume.


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES